New Clot-Busting device could ease Long-Term leg pain
NCT ID NCT07622212
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two medical devices used to remove large blood clots from the leg veins. About 180 adults with acute deep vein thrombosis (DVT) will receive either the ClotTriever System or an aspiration device. The goal is to see which device clears clots better and reduces the risk of post-thrombotic syndrome, a condition causing chronic leg pain and swelling.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ClotTriever System and aspiration thrombectomy devices
- What this could lead to
- If successful, this could identify a better device for removing blood clots in the leg, potentially reducing long-term complications like pain and swelling.
- What could go wrong
- This is a relatively small, early-stage comparison study. Results may not apply to all patients, and both procedures carry risks like bleeding or vessel damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 180 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2024
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
180
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Aged between 18 and 85 years; 2. Diagnosed with acute iliofemoral venous thrombosis, with thrombosis involving at least the iliac vein and common femoral vein; 3. Time from symptom onset to endovascular treatment ≤ 14 days; 4. Patients undergo endovascular treatment with percutaneous mechanical thrombectomy; 5. Patients sign the informed consent form. Exclusion Criteria: 1. Presence of PTS in the limb to be treated in this procedure, or a history of symptomatic DVT in the same limb within the past 2 years; 2. Concurrent symptomatic acute DVT involving the iliac vein and/or common femoral vein in the contralateral limb; 3. Known allergy to heparin, low molecular weight heparin, contrast agents, etc. 4. Concomitant severe pulmonary embolism with hemodynamic changes, such as hypoxia, hypotension, etc. 5. Inability to tolerate endovascular treatment due to conditions such as acute systemic illness, severe dyspnea, etc. 6. Concomitant severe renal insufficiency with creatinine clearance \< 30 ml/min; 7. Concomitant active bleeding, severe hepatic insufficiency, bleeding tendency, etc. 8. Concomitant severe anemia (hemoglobin \< 8.0 mg/dL) or platelet count \< 80,000/mL; 9. History of subarachnoid hemorrhage, intracranial hemorrhage, intracranial vascular malformation, or intracranial aneurysm; 10. Pregnant women; 11. Presence of other diseases (e.g., advanced malignancy, cardiac insufficiency, etc.) with an expected life expectancy \< 24 months 12. Participation in any drug or medical device clinical trial that may interfere with this study within the past 1 month; 13. Patients unwilling to participate in this trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Deep vein thrombosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Renji hospital
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can electronic alerts and patient teaching stop deadly clots after cancer surgery?
- A quick ultrasound in the ER: could it replace blood tests for blood clots?
- Simple 5-Step nursing plan could slash deadly clot risk after hip surgery
- Timing of blood thinners after childbirth bleeding may prevent clots without causing more harm
- New fingerstick test for blood thinner monitoring put to the test
- New Finger-Prick test could speed up blood clot diagnosis